Pfizer (XKAZ:PFE_KZ) Cash-to-Debt

: 0.18 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Pfizer's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.18.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Pfizer couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Pfizer's Cash-to-Debt or its related term are showing as below:

XKAZ:PFE_KZ' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.18 Med: 0.46 Max: 0.99
Current: 0.18

During the past 13 years, Pfizer's highest Cash to Debt Ratio was 0.99. The lowest was 0.18. And the median was 0.46.

XKAZ:PFE_KZ's Cash-to-Debt is ranked worse than
77.48% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs XKAZ:PFE_KZ: 0.18

Pfizer Cash-to-Debt Historical Data

The historical data trend for Pfizer's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Pfizer Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

0.19

0.32

0.84

0.65

0.18

Pfizer Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt																0.65	0.57	0.69	0.70	0.18

Competitive Comparison

For the Drug Manufacturers - General subindustry, Pfizer's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pfizer Cash-to-Debt Distribution

For the Drug Manufacturers industry and Healthcare sector, Pfizer's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Pfizer's Cash-to-Debt falls into.

Pfizer Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Pfizer's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	12690	/	(10346	+	60499)
	=	0.18

Pfizer's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	12690	/	(10346	+	60499)
	=	0.18

Pfizer (XKAZ:PFE_KZ) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Pfizer Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Pfizer's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Pfizer (XKAZ:PFE_KZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (XKAZ:PFE_KZ) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

PFE:USA PFE:Peru PFE:Mexico 1PFE:Italy PFEd:UK 0Q1N:UK PFE:Germany PFE:Chile PFE:Canada PFIZ34:Brazil PFE:Austria PFE:Argentina

Address

66 Hudson Boulevard East, New York, NY, USA, 10001-2192

Website

https://www.pfizer.com

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Pfizer (XKAZ:PFE_KZ) Headlines

No Headlines